Who's who

3 Houston innovators to know this week

From smart home technology to higher education institutions, these leaders are pushing forward innovation in Houston. Courtesy photos

Another week, another set of Houston innovators to keep your eye on. This week's edition crosses retail technology with higher education — both on this planet and beyond.

From tech that's orbiting the planet to tech that's in your very home, here are the Houston-based innovators to know.

Leah Barton, North American commercial director for Hive

Leah Barton oversees Hive's growing North American efforts from the Houston office. Courtesy of Hive

United Kingdom-based Hive, a smart product company, has bet on Houston as its battle ground for growth in the United States. The company recently tasked Leah Barton as North American Commercial Director to serve in the Houston office as of June 2019 and focus on this growth. Barton tells InnovationMap that she feels Houston is increasingly becoming an innovation hub.

"We know we've got the technical talent, we've got people who are interested in technology, whether it's from the medical angle, energy angle, aerospace angle," she says. Continue reading the story about Hive and Barton's plans for expansion by clicking here.

David Alexander, director of the Rice University Space Institute

David Alexander of the Rice University Space Institute says Houston's past accomplishments in space aren't all the Space City has to offer. Photo courtesy of Rice University

For David Alexander, director of the Rice University Space Institute, Houston's role in space exploration is far from over. In fact, even though it's been 50 years since Neil Armstrong phoned home to Houston from the moon, he argues that this moment is not all the Space City has to celebrate.

"In Houston, we tend to think of space as a destination, but it really is a resource," he says. "And we need to be thinking about it as a resource." Read the complete interview with Alexander by clicking here.

Paul Pavlou, dean of C. T. Bauer College of Business at the University of Houston

Paul Pavlou has been named as the dean of C. T. Bauer College of Business at the University of Houston. Courtesy of UH

Success is in the details for this new University of Houston C.T. Bauer College of Business dean, Paul Pavlou, who began his UH career earlier this month. Pavlou has a passion for higher education and the doors it has opened for him.

"My life was transformed by higher education," Pavlou says. "So, I feel the need to give back in terms of helping other students — especially of modest means like myself to do well in life and get a good job."

Pavlou has multidisciplinary efforts on his mind, as well as data and technology integration within the school's programs. To read more about Pavlou, click here.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted